10× Cheaper, Equally Safe Insulin Exists. Let's Bring It to America.

Why You Should Be Outraged

Americans are dying because bureaucracy makes insulin artificially expensive. The same vial costs \$300 in America, \$30 in Germany, \$25 in the UK—not because it's different or less safe, but because FDA forces manufacturers to re-prove what Europe, Britain, and Japan already confirmed using **identical safety standards**. Diabetics ration insulin, skip doses, end up in emergency rooms. Some die. Meanwhile, your government wastes \$4-5 billion annually on inflated Medicare/Medicaid insulin prices while affordable versions sit blocked by redundant paperwork.

Why This Will Work

Patients get the same insulin, 90% cheaper. **Taxpayers** save \$4-5B annually—no new taxes. **Businesses** compete fairly on a level playing field. **Doctors** gain treatment options. **Safety** is unchanged—FDA keeps full authority for inspections, recalls, and enforcement. We just stop making patients pay twice for the same review.

It's bipartisan: Progressives want affordable healthcare. Conservatives want deregulation and markets. This delivers both.

Why This Time Is Different

Past attempts used "importation" laws (§§384, 804) that **exclude biologics**—pharma killed them in court. **This Order uses biosimilar authority (§262(k)) and shortage response (§356c)** instead. We're accelerating FDA review by accepting trusted allied assessments, which FDA can already legally do.

Anti-bureaucracy mechanisms:

- Every deadline public; 5-day delays require written justification naming the blocking office
- 10-day delays escalate to Deputy Secretary + White House
- 48-hour clearance turnarounds or legal citation required
- 10-15 day reviews with public variance memos if missed
- Funded by existing BsUFA user fees (Congress can't defund via rider)
- OMB tracks as Presidential Priority with quarterly performance reviews

Previous orders agencies could ignore. This has enforcement architecture.

What Happens Next

Within 30 days: 10-page streamlined application published Within 60-120 days: First affordable insulin on shelves

FDA relies on EMA/MHRA/PMDA reviews, coordinates with pharmacies, launches price

dashboards

Same safety. Faster access. Lower prices.

We are your Polish friends and allies. We have no financial interest—just a solution to stop Americans dying from preventable insulin rationing. When trusted partners already proved medicine is safe, America shouldn't make patients pay twice.

We ask President Trump to sign this. Now. Every month we wait, people die. This costs nothing, saves billions, saves lives. Sign it.